Participating Companies

Antev
Phase 3 ready, Teverelix, a long acting injectable peptide GnRH antagonist. Lead indication for prostate cancer, followed by benign prostatic hyperplasia (BPH), acute urinary retention (AUR), uterine fibroids and endometriosis. Over 450 subjects have been dosed over 850 times to date with no serious adverse reactions and good local tolerance. [more information]

Apexigen
CD40 agonist mAb; 170+ pts dosed (mono & combi settings). 7 ongoing Ph 2s, undisclosed ocular disease program in Ph 3. AACR: Ph 1b data (w/Parker Inst); collabs w/BMY, MDACC, Yale, et al [more information]

AsclepiX Therapeutics
AXT107 demonstrated efficacy and durability in rabbit and mouse models that is superior to standard of care Eyelea. [more information]

BlinkBio, Inc.
They have innovated a platform based on Tunable Drug Conjugate (TDCs) therapies used to directly target the delivery of toxins to tumors. The lead therapeutic program targets Folate Receptor alpha and has been validated in the clinic by ADCs, providing a de-risked benchmark for platform validation and candidate development. [more information]

Caribou Biosciences
Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality. [more information]

CureVac AG
Curevac is a private German company with mRNA platform, diversified pipeline, and three lead programs in ph1: CV8102 (various cancer indications), CV9202 (NSCLC) and CV7202 (Rabies). Last financing round done at over $1bn. Other companies in the space: MRNA, TBIO, BNTX. [more information]

Elstar Therapeutics, Inc.
Elstar Therapeutics is fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating antibody-based, multi-functional therapeutics. Elstar’s Universal Targeted Immunotherapy (UniTI™) platform is positioned to overcome barriers that are limiting the full potential of other promising immunotherapeutic approaches. [more information]

Goldfinch Bio
Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney diseases. [more information]

Grace Therapeutics
: self-funded - 2 Ph 3 programs in subarachnoid hemorrhage (NDA filing in 2019) and ataxia telangiecstasia, 1 Ph 2/3 in postherpetic neuralgia (PHN) [all approved orphan designation]; 2 add’l programs (trigeminal neuralgia & aortic aneurysm). [more information]

Intensity Therapeutics
Subsidiary of Portage Biotech (seed investor in Biohaven). Raised $10m Series A in June 2016 (Investors: FastForward Innovations, Batterson VC, VCapital, Declan Doogan, Jim Mellon). Initiated FIH trial to study effects in solid tumors; trial aims to enroll 60 patients w different types of advanced solid tumor malignancies in a multicycle dosing regimen [more information]

iOx Therapeutics
Subsidiary of Portage Biotech (seed investor in Biohaven). Launched by Ludwig Cancer Research & University of Oxford. Developing multiple synthetic lipid compounds discovered by research team led by Professor Vincenzo Cerundolo; Launching first clinical trial in partnership with UK Medicines and Health Products Regulatory Agency & headed by Professor Mark Middleton (Oxford) [more information]

NexImmune, Inc.
Antigen-specific T cell therapy. Synthetic nanoparticles decorated w a combo of multiple tumor relevant antigens and co-stimulatory signals engaging directly w targeted T cells. Multiple IND filings exp H1'19. [more information]

Oyster Point Pharmaceuticals
The company’s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the Trigeminal Parasympathetic Pathway to activate the glands responsible for tear film production. [more information]

Pharvaris
Pharvaris is focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. POC was demonstrated in a monkey model and it’s applicable to all patients in HAE. [more information]

PsiOxus Therapeutics
The therapy (NG-348), uses virus to transport two therapeutic genes directly into tumors to recruit immune cells into attacking targeted cancer cells. Upcoming Milestones: - 2 programs in clinic with readouts in 2019 (ovarian cancer in comb w Paclitaxel, carcinomas in comb w nivolumab) - 2 INDs in 2018 (NG-348 and NG-350A) - 2 INDs in 2019 (NG-641 and NG-347) [more information]

Quentis Therapeutics
Lead program is a first-in-class IRE1α inhibitor designed to boost anti-tumor immunity in cancer. Quentis is pursuing therapies to address multiple ER stress pathway targets in the tumor micro-environment, as well as in other diseases where ER stress plays an important role. Quentis launched in February 2018 with a $48 million Series A financing. [more information]

Rapt Therapeutics
[RAPT]
US$535 MM MCap
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. [more information]

Tango Therapeutics
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of targeted therapies to people with cancer. [more information]

TRIGR Therapeutics
Bispecific Abs: dual angiogenesis inhibitor (TR009) and 3 immunomodulatory dual checkpoint & T cell engaging BsAbs. ASCO TR009 P1a results. Interim P1a dose escalation: clin benefit of 66%, one PR (7.5mg) no DLTs in solid tumors [more information]

Viela Bio
[VIE]
US$1,321 MM MCap
Developing novel therapies for wide range of autoimmune and severe inflammatory diseases, focusing on shared critical biological pathways to target underlying cause of disease [more information]